“…The morphology, neurophysiology and neuropharmacology of the mouse CSC-SCG has received considerable investigation over the years (Black et al, 1972;Yokota and Yamauchi, 1974;Banks and Walter, 1975;Inoue, 1975;Lewis and Burton, 1977;Forehand, 1985;Kidd and Heath, 1988;Gibbins, 1991;Kasa et al, 1991;Little and Heath, 1994;Jobling and Gibbins, 1999;El-Fadaly and Kummer, 2003;David et al, 2010;Cadaveira-Mosquera et al, 2012;Pashai et al, 2012;Alberola-Die et al, 2013;Liu and Bean, 2014;Martinez-Pinna et al, 2018;Mitsuoka et al, 2018;Feldman-Goriachnik and Hanani, 2019;Simeone et al, 2019;Rivas-Ramírez et al, 2020). Mouse tissues that receive post-ganglionic projections from the SCG have also been heavily investigated (Krieger et al, 1976;García et al, 1988;Kawaja and Crutcher, 1997;Maklad et al, 2001;Pankevich et al, 2003a,b;Ivanusic et al, 2013;Karlsen et al, 2013;Lindborg et al, 2018;Ziegler et al, 2018;Teshima et al, 2019). Nonetheless, there is no direct evidence that the CSC-SCG complex innervates the carotid bodies of mice, and this is likely on the basis of the presence of sympathetic (i.e., tyrosine-hydroxylase-positive) nerve terminals and adrenergic receptors in these structures (Prieto-Lloret et al, 2007;Roux et al, 2008;Kåhlin et al, 2010;…”